Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 124

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 124
---
4 and for the period commencing January 1, 2024, to July 23, 2024 and for the year ended December 31, 2023, and 2022, are as follows:

|                                                                                 |     | Successor unaudited 
 2024                | For the period commencing July 24 
              through September 30 |     | Predecessor audited 
 2024                | For the period commencing January 1 
                             through 
                             July 23 |     | 2023 |   Year ended 
 December 31, |     | 2022 |         |
|:--------------------------------------------------------------------------------|:----|:--------------------|----------------------------------:|:----|:--------------------|------------------------------------:|:----|:-----|-------------:|:----|:-----|--------:|
| Numerator:                                                                      |     |                     |                                   |     |                     |                                     |     |      |              |     |      |         |
| Net loss applicable to shareholders of Ordinary Share                           |     |                     |                               770 |     |                     |                               1,421 |     |      |          987 |     |      |     436 |
| Denominator:                                                                    |     |                     |                                   |     |                     |                                     |     |      |              |     |      |         |
| Shares of Ordinary Share used in computing basic and diluted net loss per share |     |                     |                        40,614,026 |     |                     |                             143,447 |     |      |      137,603 |     |      | 120,326 |
| Net loss per share of Ordinary Share, basic and diluted                         |     |                     |                              0.02 |     |                     |                                9.38 |     |      |         7.72 |     |      |    3.62 |

<div align='center'>F-17</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands, except share and per share data

NOTE 6 – CASH AND CASH EQUIVALENTS

|                  |     |     Successor |       |     | Predecessor |     |     |              |       |     |      |     |
|                  |     |     Unaudited |       |     |     Audited |     |     |              |       |     |